sorafenib has been researched along with Cardiac Toxicity in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 11 (64.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bouitbir, J; Krähenbühl, S; Panajatovic, MV | 1 |
| Hou, Y; Jiang, H; Li, J; Li, Y; Li, Z; Wang, C; Yang, X; Zhang, A | 1 |
| Eltelbany, RFA; Khalil, HMA; Rasheed, RA; Zaafar, D; Zaitone, SA | 1 |
| Chen, YT; Fang, YH; Hsiao, YW; Hsu, LW; Liu, PY; Liu, YW; Masbuchin, AN; Rohman, MS; Wang, JM; Wu, SN; Yen, CJ | 1 |
| Boswell, SA; Chung, M; Han, S; He, Z; Li, J; Wang, H; Wang, Y; You, F | 1 |
| Abo El-Magd, NF; El Gayar, AM; Yousef, EH | 1 |
| El-Gazzar, MGM; El-Hazek, RMM; El-Sabbagh, WA; Fadel, NA; Zaher, NH | 1 |
| Guo, Y; Han, JY; Liu, S; Wang, H; Yue, S | 1 |
| Gao, C; Hu, H; Jiang, X; Liang, F; Liu, M; Ma, W; Zhan, H; Zhang, X; Zhao, L; Zhao, Z | 1 |
| Abdelgalil, AA; Ahamad, SR; Al-Jenoobi, FI; Mohamed, OY | 1 |
| Dame, K; Grafton, F; Loewke, K; Maddah, M; Mandegar, MA; Ribeiro, AJS | 1 |
| Bardelang, D; Huang, Q; Lee, SMY; Wang, C; Wang, R; Yang, X | 1 |
| Angus, SP; Beak, JY; Chen, X; Hicks, ST; Huang, W; Jensen, BC; Johnson, GL; Parry, TL; Sciaky, N; Stuhlmiller, TJ; Willis, MS; Zawistowski, JS | 1 |
| Arain, S; Balanescu, DV; Donisan, T; Gould, KL; Hassan, S; Iliescu, C; Karimzad, K; Kim, P; Lopez-Mattei, J; Palaskas, N; Sudasena, D | 1 |
| Boswell, SA; Erickson, AR; Everley, RA; Haigis, MC; Holton, KM; Jacobson, CA; Maliszewski, L; Palmer, AC; Ringel, AE; Ron-Harel, N; Sheehan, RP; Sorger, PK; Wang, H | 1 |
| Kawabata, M; Kuroyanagi, J; Miyabe, M; Nishimura, Y; Shimada, Y; Tanaka, T; Umemoto, N; Zhang, B | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
1 review(s) available for sorafenib and Cardiac Toxicity
| Article | Year |
|---|---|
Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2014 |
16 other study(ies) available for sorafenib and Cardiac Toxicity
| Article | Year |
|---|---|
Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line.
Topics: Animals; Apoptosis; Cardiotoxicity; Cell Line; Electron Transport; Glycolysis; Imatinib Mesylate; Membrane Potential, Mitochondrial; Mitochondria, Heart; Mitochondrial Membranes; Myoblasts, Cardiac; Myocytes, Cardiac; Oxidative Stress; Rats; Sorafenib | 2022 |
ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis.
Topics: Activating Transcription Factor 4; Animals; Cardiotoxicity; Ferroptosis; Liver Neoplasms; Mice; Sorafenib | 2022 |
Hesperetin mitigates sorafenib-induced cardiotoxicity in mice through inhibition of the TLR4/NLRP3 signaling pathway.
Topics: Animals; Cardiotoxicity; Hesperidin; Interleukin-6; Male; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sorafenib; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2022 |
Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK/JNK signalling pathways.
Topics: Animals; C-Reactive Protein; Carcinoma, Hepatocellular; Cardiotoxicity; Female; Humans; Liver Neoplasms; Male; Mitochondria; Protein Kinase Inhibitors; Sorafenib; Tyrosine Kinase Inhibitors | 2023 |
Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes.
Topics: Animals; Apoptosis; Cardiotoxicity; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Myocytes, Cardiac; Protein Serine-Threonine Kinases; Rats; Sorafenib; Tyrosine Kinase Inhibitors | 2023 |
Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Liver Neoplasms; Rats; Sorafenib; Thioacetamide; TRPM Cation Channels | 2023 |
Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact.
Topics: Animals; Carcinoma, Hepatocellular; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Liver Neoplasms; Mice; Myocytes, Cardiac; Sorafenib; Sulfapyridine; Vascular Endothelial Growth Factor Receptor-2 | 2023 |
Sorafenib induces cardiotoxicity through RBM20-mediated alternative splicing of sarcomeric and mitochondrial genes.
Topics: Adenosine Triphosphate; Alternative Splicing; Animals; Cardiotoxicity; Formins; Genes, Mitochondrial; Humans; Myocytes, Cardiac; Rats; RNA-Binding Proteins; Sarcomeres; Sorafenib | 2023 |
Cardiotoxicity of sorafenib is mediated through elevation of ROS level and CaMKII activity and dysregulation of calcium homoeostasis.
Topics: Animals; Antineoplastic Agents; Antioxidants; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiotoxicity; Male; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sorafenib | 2020 |
The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat.
Topics: Animals; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Heart; Heart Rate; Losartan; Male; Metabolomics; Myocardium; Protein Kinase Inhibitors; Rats, Wistar; Sorafenib | 2020 |
Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
Topics: Antineoplastic Agents; Biological Assay; Cardiotoxicity; Cells, Cultured; Deep Learning; Doxorubicin; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Hepatocytes; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Sorafenib; Tamoxifen; Toxicity Tests | 2020 |
Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cardiotoxicity; Cell Line, Tumor; Cell Survival; Embryo, Nonmammalian; Humans; Imidazoles; Macromolecular Substances; Magnetic Resonance Spectroscopy; Molecular Structure; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Sorafenib; Zebrafish | 2017 |
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Recepto
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cells, Cultured; Dose-Response Relationship, Drug; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids; Female; Gene Expression Profiling; Heart; Heart Diseases; Indoles; Mice; Molecular Targeted Therapy; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Pyrroles; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Time Factors | 2017 |
Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib.
Topics: Adult; Antineoplastic Agents; Cardiotoxicity; Cardiovascular Agents; Coronary Artery Disease; Coronary Restenosis; Defibrillators; Defibrillators, Implantable; Drug-Eluting Stents; Electric Countershock; Endovascular Procedures; Humans; Intra-Aortic Balloon Pumping; Leukemia, Myeloid, Acute; Male; Myocardial Infarction; Peripheral Arterial Disease; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2019 |
Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.
Topics: Acclimatization; Antineoplastic Agents; Cardiotoxicity; Cell Differentiation; Cells, Cultured; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Induced Pluripotent Stem Cells; Lapatinib; Myocytes, Cardiac; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib | 2019 |
Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.
Topics: Adult; Animals; Antineoplastic Agents; Cardiotoxicity; Down-Regulation; Glycoproteins; Heart; Humans; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib; Ventricular Dysfunction; Zebrafish | 2015 |